Field evaluation of a mobile biosafety laboratory in Senegal to strengthen rapid disease outbreak response and monitoring.
MBS-Lab
Senegal
field deployment
mobile biosafety laboratory
outbreak
point-of-care
Journal
African journal of laboratory medicine
ISSN: 2225-2002
Titre abrégé: Afr J Lab Med
Pays: South Africa
ID NLM: 101603205
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
04
2019
accepted:
29
05
2020
entrez:
16
9
2020
pubmed:
17
9
2020
medline:
17
9
2020
Statut:
epublish
Résumé
Past and recent outbreaks have highlighted the vulnerability of humans to infectious diseases, which represent serious economic and health security threats. A paradigm shift in the management of sanitary crises is urgently needed. Based on lessons from the 2014 Ebola outbreak, the Praesens Foundation has developed an all-terrain mobile biosafety laboratory (MBS-Lab) for effective field diagnostics capabilities. The aim of the study was to train African teams and run a field evaluation of the MBS-Lab, including robustness, technical and operational sustainability, biosafety, connectivity, turn-around times for testing and result delivery. The MBS-Lab was deployed in Senegal in October 2017 for a six-month field assessment under various ecological conditions and was mobilised during the dengue outbreaks in 2017 and 2018. The MBS-Lab can be considered an off-grid solution that addresses field challenges with regard to working conditions, mobility, deployment, environment and personnel safety. Blood ( The MBS-Lab is an innovative solution for outbreak response, even in remote areas. The study demonstrated successful local ownership and community engagement. The MBS-Lab can also be considered an open mobile healthcare platform that offers various opportunities for field-deployable, point-of-care technologies for surveillance programmes.
Sections du résumé
BACKGROUND
BACKGROUND
Past and recent outbreaks have highlighted the vulnerability of humans to infectious diseases, which represent serious economic and health security threats. A paradigm shift in the management of sanitary crises is urgently needed. Based on lessons from the 2014 Ebola outbreak, the Praesens Foundation has developed an all-terrain mobile biosafety laboratory (MBS-Lab) for effective field diagnostics capabilities.
OBJECTIVE
OBJECTIVE
The aim of the study was to train African teams and run a field evaluation of the MBS-Lab, including robustness, technical and operational sustainability, biosafety, connectivity, turn-around times for testing and result delivery.
METHODS
METHODS
The MBS-Lab was deployed in Senegal in October 2017 for a six-month field assessment under various ecological conditions and was mobilised during the dengue outbreaks in 2017 and 2018.
RESULTS
RESULTS
The MBS-Lab can be considered an off-grid solution that addresses field challenges with regard to working conditions, mobility, deployment, environment and personnel safety. Blood (
CONCLUSION
CONCLUSIONS
The MBS-Lab is an innovative solution for outbreak response, even in remote areas. The study demonstrated successful local ownership and community engagement. The MBS-Lab can also be considered an open mobile healthcare platform that offers various opportunities for field-deployable, point-of-care technologies for surveillance programmes.
Identifiants
pubmed: 32934915
doi: 10.4102/ajlm.v9i2.1041
pii: AJLM-9-1041
pmc: PMC7479379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1041Informations de copyright
© 2020. The Authors.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Biomed Res Int. 2017;2017:5245021
pubmed: 28286767
Nature. 2019 Mar;567(7747):147
pubmed: 30858557
PLoS One. 2014 Oct 31;9(10):e110435
pubmed: 25360527
J Travel Med. 2019 Oct 14;26(7):
pubmed: 30407572
J Mol Diagn. 2019 Sep;21(5):862-872
pubmed: 31443844
BMC Infect Dis. 2015 Feb 12;15:52
pubmed: 25888024
PLoS One. 2014 Jun 16;9(6):e99392
pubmed: 24932493
PLoS Negl Trop Dis. 2017 May 15;11(5):e0005622
pubmed: 28505171
Euro Surveill. 2010 Feb 18;15(7):
pubmed: 20184854
Pathog Glob Health. 2014 Dec;108(8):349-55
pubmed: 25491436
Niger Med J. 2017 Jan-Feb;58(1):1-6
pubmed: 29238121
PLoS Pathog. 2013 Jan;9(1):e1003105
pubmed: 23349630
Emerg Infect Dis. 2014 Mar;20(3):456-9
pubmed: 24572297
Travel Med Infect Dis. 2019 Mar - Apr;28:107-108
pubmed: 30408524
Lancet. 2015 May 9;385(9980):1884-901
pubmed: 25987157
Emerg Infect Dis. 2003 Mar;9(3):362-7
pubmed: 12643833
Microbiol Insights. 2018 Feb 13;11:1178636118758651
pubmed: 29467579
Malar J. 2017 Oct 13;16(1):413
pubmed: 29029619
PLoS Negl Trop Dis. 2017 Jun 19;11(6):e0005665
pubmed: 28628619
Health Secur. 2018 Fall;16(S1):S103-S110
pubmed: 30480496
Crit Care Clin. 2013 Jul;29(3):485-507
pubmed: 23830650
Malar J. 2016 Jan 28;15:47
pubmed: 26821709